Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547916 | 0.82 | GABRA1 (0.46) | ACHEESR1CYP1A2TSHRCYP3A4 | |
| SCHEMBL21608733 | 0.80 | ACHE (0.37) | ACHEESR1CYP1A2TSHRCYP3A4 | |
| SCHEMBL4455674 | 0.80 | P2RX7 (0.44) | P2RX7ACHECYP1A2TSHRCYP3A4 | |
| SCHEMBL30846952 | 0.80 | P2RX7 (0.44) | P2RX7ACHECYP1A2TSHRCYP3A4 | |
| SCHEMBL23520552 | 0.78 | CYP1A2 (0.45) | ACHEESR1CYP1A2TSHRCYP3A4 | |
| SCHEMBL1642111 | 0.78 | HTR2C (0.38) | ACHEESR1CYP1A2TSHRCYP3A4 | |
| SCHEMBL16958041 | 0.78 | ACHE (0.36) | ACHEESR1CYP1A2TSHRCYP3A4 | |
| SCHEMBL29945863 | 0.78 | CYP1A2 (0.45) | ACHEESR1CYP1A2TSHRCYP3A4 | |
| SCHEMBL23526532 | 0.78 | CYP1A2 (0.45) | ACHEESR1CYP1A2TSHRCYP3A4 | |
| SCHEMBL16951322 | 0.77 | ACHE (0.39) | ACHEESR1CYP1A2TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023088420-A1 | 1H-BENZO[B]AZEPIN-2(3H)-ONE COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2023-05-25 | — | — | WO | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-20200405697-A1 | Antitumor Agent | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-31 | — | — | US | disclosed |
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-24 | — | — | US | disclosed |
| EP-3718545-A1 | ANTITUMOR AGENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-10-07 | — | — | EP | disclosed |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-05-21 | — | — | US | disclosed |
| WO-2017209155-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | 大鵬薬品工業株式会社 | 2017-12-07 | — | — | WO | disclosed |
| CN-1980889-B | Adamantyl pyrrolidin-2-one derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase | JANSSEN PHARMACEUTICA NV | 2010-11-10 | — | — | CN | disclosed |
| CN-101341133-A | Quinazoline derivatives, process for their preparation and their use as anti-cancer agents | ASTRAZENECA AB (SE) | 2009-01-07 | — | — | CN | disclosed |
| CN-101048388-A | Quinazolinone derivatives and their use as B-Raf inhibitors | ASTRAZENECA AB (SE) | 2007-10-03 | — | — | CN | disclosed |
| CN-1980889-A | Adamantyl pyrrolidin-2-one derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399235-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | P2RX7 3672/4885ACHE 4707/4885ESR1 2532/4885 |
| US-20200157066-A1 | Sulfonamide Compound or Salt Thereof | RNASEH1, SNRPA1, RRM2 | P2RX7 3672/4885ACHE 4707/4885ESR1 2532/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | P2RX7 3672/4885ACHE 4707/4885ESR1 2532/4885 |
| US-20200405697-A1 | Antitumor Agent | HNRNPR, RRM2, RRM2B | P2RX7 3886/4885ACHE 4837/4885ESR1 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.